PODD

ACCE-researched
Insulet Corporation Common Stock
Healthcare · Medical Devices · NASDAQ · United States
$140.60-0.67%
Market cap $9.8BNext earnings 2026-11-05Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$140.60+0.0%
confidence-weighted across 5 of 6 models
Now $140.60
$140.60
$41.11$206.98
TrimBronze45
Price vs fair value
22.8% above
-18.6% to fair value
ACCE score
62
out of 100
Analysts
88% buy
24 covering
P/E
26.4x
forward 18.2x
1-year return
-57.8%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 2 flags
  • high
    Institutional ownership anomaly
    Institutional ownership at 106% suggests significant short positions or data error, creating potential volatility risk.
  • moderate
    Momentum score collapse
    ACCE momentum score of 17/100 indicates significant recent underperformance despite strong fundamentals.
Reports in 45 days, last quarter beat by 0.2%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

-58.0% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish88% buy · 24 covering analysts
● Strong buy 17● Buy 4● Hold 3● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 17% of peers
low 0.0x26.4xhigh 45.8x
ROEbetter than 100% of peers
low -26%26%high 26%
Div yieldbetter than 83% of peers
low 0.0%0.0%high 0.3%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
DEMANT.CODemant A/S$9.7B26.223.3%1.790.0%-Compare
GKOSGlaukos Corporation Common Stock$9.7B--26.0%0.070.0%-Compare
GMEDGlobus Medical Inc. Class A Common Stock$9.9B18.911.8%0.000.0%-Compare
TXG10x Genomics Inc. Class A Common Stock$10.0B--9.4%0.010.0%-Compare
BIOBio-Rad Laboratories Inc. Class A Common Stock$10.1B45.83.1%0.160.0%-Compare
BRKRBruker Corporation Common Stock$9.4B--3.0%0.760.3%-Compare

Sector report card

Where PODD ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 45 days, last quarter beat by 0.2%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+6.5%
1 month
-7.2%
3 months
-3.5%
6 months
-38.1%
YTD
-50.5%
1 year
-57.8%

SEC filings

40 filings
September 2026
Sep 16
8-KCurrent reportPeriod 2026-09-14
Sep 10
8-KCurrent reportPeriod 2026-09-03
August 2026
Aug 24
Form 4Insider transactionPeriod 2026-08-21
37 more filings + AI summaries on Investor+.INVESTOR